Gene Kinney

[Prothena Corporation @ProthenaCorp]

#BreakingNews: Today, we’re excited to share that @novonordisk successfully completed a Phase 2 trial with coramitug (formerly PRX004) and is expected to advance the program into Phase 3 development for ATTR #amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Read more: https://t.co/3zXYM2ntNJ

[Prothena Corporation @ProthenaCorp]

Chad Swanson, Chief Development Officer, joined the “Improving the Therapeutic Potential of Immunotherapies in AD” session at #ADPD2025, where experts came together to discuss the latest research and strategies in slowing disease progression. We stand alongside the #AlzheimersDisease community and are committed to continued research, collaborate, and drive innovation for patients and their families.

[Gene Kinney @GGKinney]

We’re excited to share our latest updates as we continue advancing therapies for patients affected by diseases caused by protein dysregulation. 2025 will be a transformational year for @ProthenaCorp, with meaningful progress across our R&D portfolio. #amyloidosis #alzheimers

[Prothena Corporation @ProthenaCorp]

In a conversation with President and CEO, Gene Kinney, we reflect on 2024, discuss what lies ahead for Prothena in 2025 and our ongoing commitment to developing therapies for patients affected by protein dysregulation. Learn more: https://t.co/QIutrtIR5M

[Prothena Corporation @ProthenaCorp]

In a conversation with President and CEO, Gene Kinney, we reflect on 2024, discuss what lies ahead for Prothena in 2025 and our ongoing commitment to developing therapies for patients affected by protein dysregulation. Learn more: https://t.co/QIutrtIR5M

[Prothena Corporation @ProthenaCorp]

Participation in the AFFIRM-AL study will help us understand whether an investigational medication is effective for adults newly diagnosed with advanced AL #amyloidosis. Learn more about participating: https://t.co/3kwlkw0CQu

[Prothena Corporation @ProthenaCorp]

As we enter 2025, our CEO Gene Kinney, highlights our ongoing commitment to supporting the millions affected by neurodegenerative & rare peripheral amyloid diseases. Here’s to a year of continued progress, collaboration, & meaningful impact for the patients & their loved ones.

[Prothena Corporation @ProthenaCorp]

As 2024 comes to a close, we reflect on a remarkable year at Prothena. We want to extend our warmest wishes for a happy and prosperous New Year to our Prothena family, partners in advocacy, and the patients and caregivers we serve. #HappyHolidays

[Prothena Corporation @ProthenaCorp]

#DYK NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend primary treatment for AL #amyloidosis is in a clinical trial? Visit our booth (2027) at #ASH24 to learn more about the AFFIRM-AL clinical trial in Mayo Stage IV AL amyloidosis.

[Prothena Corporation @ProthenaCorp]

Join us for our Friday Satellite Symposium, preceding #ASH24. We are proud to sponsor the independent Medscape CME Symposium, “Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis,” tomorrow at 11:30am PT.

[Prothena Corporation @ProthenaCorp]

This #WorldAmyloidosisDay, we stand with patients, families, and all others affected by this #raredisease. At Prothena, we remain deeply committed to advancing treatment options and making a difference for the #amyloidosis community.

[Boston U Chobanian & Avedisian School of Medicine @BUMedicine]

BU and BMC’s Vaishali Sanchorawala, MD, is leading a new study along with the Dana-Farber Cancer Institute for people with advanced stages of AL amyloidosis in Boston. To read more from the Boston Globe, click here: https://t.co/GB8jinSP8N

[Gene Kinney @GGKinney]

#Alzheimers research is making incredible strides. This article in @Forbes discusses the development of next-generation vaccines, including our work at @ProthenaCorp, with the potential to offer new hope for patients and their families. Read more: https://t.co/8apLNhoxj2

[Prothena Corporation @ProthenaCorp]

AL #amyloidosis can be challenging to diagnose due to its varied symptoms. Hear from those impacted by this #raredisease and the challenges they faced in putting the puzzle pieces together: https://t.co/1OxqcrMhZP

[Prothena Corporation @ProthenaCorp]

This year, we proudly joined @Amyloidosisfdn's Virtual Run/Walk/Roll/Bike Event, spreading awareness in support of #amyloidosis within our local communities. Across the US and EU, our teams came together to participate in this impactful event! #RunForAmyloidosis

[Gene Kinney @GGKinney]

A truly significant day for the #Alzheimers community, which further reinforces the disease-modifying ability of Aβ targeting therapies. We at @ProthenaCorp will continue to innovate and work with urgency to develop treatments with the patient experience top of mind.

[Prothena Corporation @ProthenaCorp]

We stand alongside the #Alzheimers community in celebrating the FDA approval of a therapy targeting amyloid beta. This milestone marks continued progress for the community. At Prothena, we continue working to pioneer the next generation of Aβ targeting treatments for Alzheimer's.

[Prothena Corporation @ProthenaCorp]

Collaborative partnerships are fundamental in driving innovation. Check out our discussion with @PharmaVoice on our transformative R&D efforts in partnership with @bmsnews, aimed at advancing treatments for CNS disorders: https://t.co/CkvLW1kGXZ

[Gene Kinney @GGKinney]

It was great speaking with @healioneurology about the latest updates from our pipeline and what’s next for @ProthenaCorp in the year ahead. We look forward to sharing more about our progress and future initiatives soon. #Alzheimer’s disease; AL #amyloidosis

[Prothena Corporation @ProthenaCorp]

Our CEO, Gene Kinney, recently sat down with @healioneurology to discuss our ongoing R&D efforts in diseases caused by protein dysregulation, including developments in #Alzheimers disease and  AL #amyloidosis. Learn more: https://t.co/QYY80wzFCV

[Prothena Corporation @ProthenaCorp]

Today's unanimous and positive FDA Peripheral and Central Nervous System Drugs Ad Comm vote marks a step forward in progress for patients, families, and caregivers in treating #Alzheimers disease.

[Prothena Corporation @ProthenaCorp]

An #amyloidosis diagnosis can leave patients & families with unanswered questions. We encourage you to check out @Amyloidosis_ARC’s patient resources to learn more about this condition & the support available to those impacted: https://t.co/mnSqeZiWDy #AmyloidosisAwarenessMonth

[Prothena Corporation @ProthenaCorp]

At Prothena, we believe it’s important to elevate firsthand perspectives from patients. Watch as Linda, living with #amyloidosis, offers advice for others who are managing this disease: https://t.co/0x5p4nrzIM #AmyloidosisAwarenessMonth